StockData

Aclaris Therapeutics vs HCW Biologics

ACRS and HCWB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ACRS and HCWB compare

Aclaris Therapeutics is the larger company, worth 361 times as much as HCW Biologics ($531M against $1.5M).

HCW Biologics grew revenue faster over the last twelve months (700% versus −51.0% for Aclaris Therapeutics).

HCW Biologics keeps more of each dollar of sales as profit, with a net margin of −83.8% compared with −921% at Aclaris Therapeutics.

HCW Biologics scores higher on the StockData Score (6 against 5 for Aclaris Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricACRSHCWB
Size and price
Market cap$531M$1.5M
Share price$3.60$0.800
Change, 1 year55.4%−94.6%
Change, 5 years−71.4%−99.9%
Beta (5Y)0.962.44
Employees73–
StockData Score
Total score56 (better)
Valuation score03 (better)
Growth score02 (better)
Performance score01 (better)
Health score5 (better)0
Dividend score00
Valuation
P/S64.6×0.2× (better)
P/B4.3×0.2× (better)
FCF yield−11.7%–
Fair value$1.42$15.29
Margin of safety−155%94.8% (better)
Growth
Revenue growth (TTM)−51.0%700% (better)
Revenue growth, 5Y average3.8% (better)−57.9%
Profitability
Gross margin79.5%96.7% (better)
Operating margin−1050%−115% (better)
Net margin−921%−83.8% (better)
FCF margin−757%–
Return on equity−59.1% (better)−151%
Return on invested capital–−70.7%
Financial health
Debt / equity0.000.88 (better)
Interest coverage–−14.0×
Current ratio3.46 (better)0.06
Altman Z-score−3.16 (better)−7.20
Piotroski F-score3 (better)2
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions82.3%5.6%
Held by insiders13.3%34.9%
Insider net buying, 12 months−$1.4M$532K (better)
Short interest, % of float9.1%4.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.